The $95.1M capital infusion removes near-term financing risk and funds SZN-8141 through initial clinical data in H2 2027. Watch for the S-3 resale registration filing within 30 days post-closing and initial DUET enrollment updates.
Price Chart
Executive Summary
Surrozen received FDA clearance of its IND application for SZN-8141, a bifunctional Wnt agonist/VEGF antagonist antibody for diabetic macular edema (DME), triggering a second closing milestone under its March 2025 private placement. The second closing is expected to provide approximately $95.1 million in gross proceeds on or about October 20, 2026, funding development of SZN-8141 and SZN-8143. First patient dosing in the Phase 1b/2a DUET study is expected in Q4 2026 with initial data in H2 2027.
Key Facts
- FDA cleared IND for SZN-8141 (bifunctional Wnt agonist/VEGF antagonist antibody) for diabetic macular edema (DME).
- First patient dosing in Phase 1b/2a DUET study expected Q4 2026; initial data expected H2 2027.
- IND clearance satisfies second closing milestone under March 2025 two-tranche private placement.
- Second closing expected to provide approximately $95.1 million in gross proceeds on or about October 20, 2026.
- Proceeds to support development of SZN-8141, SZN-8143, and broader operating activities.
- Company plans to file a resale registration statement on Form S-3 within 30 days after closing.
- Also plans to develop SZN-8141 in neovascular age-related macular degeneration and other retinal vascular diseases.
Financial Impact
Approximately $95.1 million in gross proceeds from second closing of private placement, before fees and expenses.
Risk Factors
- Phase 1b/2a clinical data for SZN-8141 is not expected until H2 2027; early-stage clinical failure risk.
- Resale registration on Form S-3 may create near-term overhang from registered shares and warrants.
- Pre-revenue biotech with no approved products; relies on successful clinical development and additional capital.
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-411298 |
| Document: 0001193125-26-411298-index-headers.html | 0001193125-26-411298 |
| Document: 0001193125-26-411298-index.html | 0001193125-26-411298 |
| Document: 0001193125-26-411298.txt | 0001193125-26-411298 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 4d ago | SC 13D/A | $25.48 | awaiting T+5 | — | $27.28 (+7.06%) |
Oct 20, 2026 6d ago | 8-K | $25.32 | awaiting T+5 | — | $27.28 (+7.74%) |
Oct 20, 2026 6d ago | Press Release | $25.32 | awaiting T+5 | — | $27.28 (+7.74%) |
Oct 7, 2026 19d ago | SC 13G/A | $27.97 $25.07 | ▼ −10.37% | ▼ −10.09% | $27.28 (−2.47%) |
Oct 2, 2026 24d ago | 8-K | $29.32 $29.69 | ▲ +1.26% | ▲ +0.10% | $27.28 (−6.96%) |
Oct 2, 2026 24d ago | Press Release | $29.32 $29.69 | ▲ +1.26% | ▲ +0.10% | $27.28 (−6.96%) |
Oct 1, 2026 25d ago | SC 13G | $29.32 $29.69 | ▲ +1.26% | ▲ +0.10% | $27.28 (−6.96%) |
Aug 7, 2026 11w ago | 25-NSE | $25.09 $23.78 | ▼ −5.22% | ▼ −5.17% | $27.28 (+8.73%) |
May 4, 2026 25w ago | Insider Cluster | $32.07 $29.28 | ▼ −8.70% | ▼ −11.64% | $27.28 (−14.94%) |
Mar 23, 2026 31w ago | S-3 | $25.00 $29.13 | ▼ −16.52% | ▼ −16.94% | $27.28 (−9.12%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers